1: Interne Daten, Laboratoires URGO, Report 2023-01Ev2 (in-vitro Daten)
2: Meaume S. et al, Evaluation of two fibrous wound dressings for the management of leg ulcers: Results of a European randomised controlled trial (Earth RCT). J Wound Care, Vol 23. No 3; March 2014, 105-116
3: Interne Daten, Laboratoires URGO, Report 2011-06FV4 (in-vitro Daten)
4: Interne Daten, Laboratoires URGO, Nexidia-report-2013-09Dv4 (in-vitro Daten)
5: Interne Daten, Laboratoires URGO, RS-UR-2021-577-LAP
6: Interne Daten, Laboratoires URGO, STMT_URID_TA-TB_2024_1 (UrgoClean Border); report n°88050-2009 (UrgoClean Kompresse und Tamponade)
7: Reinboldt-Jockenhöfer F. et al: Debridement – how efficient can a wound dressing be? The answer from a large prospective observational study. J Wound Care 2025; 34(4); https://doi.org/10.12968/jowc.2025.0046. Keine Vergleichsstudie. Untersucht wurden insgesamt 1.558 Patienten, davon 220 mit lokaler Wundinfektion unter Einsatz von UrgoClean, von denen 47 nicht zusätzlich mit Antibiotika behandelt wurden.
8: Interne Daten, Laboratoires URGO, RS/UR /023-306/SOL
9: Interne Daten, Laboratoires URGO, RE/UR/2021-576/SOL
10: European Pressure Ulcer Advisory Panel, National Pressure Injury Advisory Panel and Pan Pacific Pressure Injury Alliance. Prevention and Treatment of Pressure Ulcers/Injuries: Clinical Practice Guideline. The International Guideline. Emily Haesler (Ed.). EPUAP/NPIAP/PPPIA: 2019.
11: Interne Daten, Laboratoires URGO, RS/UR/2023-070/LAP (UrgoClean Tamponade)
12: Interne Daten, Laboratoires URGO, RE/UR/2021-553/SOL